Who are Reteplase 10 U's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): reteplase 10+10 U, Oral lumbrokinase DLBS1033, Tenecteplase thrombolysis, TNKase, Intra-Arterial TNK and Albumin, thrombolysis therapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/reteplase-10-u.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Reteplase 10 U — Competitive Intelligence Brief

Reteplase 10 U (Reteplase 10 U) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fibrinolytic agent; tissue plasminogen activator (tPA). Area: Cardiovascular.

marketed Fibrinolytic agent; tissue plasminogen activator (tPA) Fibrin; plasminogen Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Reteplase 10 U (Reteplase 10 U) — The University of Texas Health Science Center, Houston. Reteplase is a fibrinolytic enzyme that breaks down blood clots by converting plasminogen to plasmin, which degrades fibrin.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Reteplase 10 U TARGET	Reteplase 10 U	The University of Texas Health Science Center, Houston	marketed	Fibrinolytic agent; tissue plasminogen activator (tPA)	Fibrin; plasminogen
reteplase 10+10 U	reteplase 10+10 U	Sahlgrenska University Hospital	marketed	Fibrinolytic agent; tissue plasminogen activator (tPA) analog	Fibrin; plasminogen
Oral lumbrokinase DLBS1033	Oral lumbrokinase DLBS1033	Universitas Sebelas Maret	marketed	Fibrinolytic enzyme	Fibrin; plasminogen activation pathway
Tenecteplase thrombolysis	Tenecteplase thrombolysis	Xuanwu Hospital, Beijing	marketed	Fibrinolytic agent / Thrombolytic	Fibrin; Plasminogen
TNKase	TNKase	Cedars-Sinai Medical Center	marketed	Fibrinolytic agent; tissue plasminogen activator (tPA)	Fibrin; plasminogen
Intra-Arterial TNK and Albumin	Intra-Arterial TNK and Albumin	Tianjin Huanhu Hospital	phase 3	Thrombolytic agent with albumin carrier	Fibrin; plasminogen
thrombolysis therapy	thrombolysis therapy	Leiden University Medical Center	phase 3	Thrombolytic agent	Fibrin; plasminogen/plasmin pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fibrinolytic agent; tissue plasminogen activator (tPA) class)

Cedars-Sinai Medical Center · 1 drug in this class
Hui-Sheng Chen · 1 drug in this class
The University of Texas Health Science Center, Houston · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Reteplase 10 U — Competitive Intelligence Brief. https://druglandscape.com/ci/reteplase-10-u. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab